Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Average Recommendation of “Moderate Buy” by Brokerages

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) has earned a consensus recommendation of “Moderate Buy” from the nine brokerages that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $60.8571.

Several equities research analysts have weighed in on KNSA shares. Jefferies Financial Group raised their price target on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a “buy” rating in a report on Tuesday, April 28th. Wells Fargo & Company raised their price target on Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the stock an “overweight” rating in a report on Wednesday, April 29th. Zacks Research raised Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a report on Monday, May 18th. Canaccord Genuity Group raised their price target on Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Finally, Citigroup raised their price target on Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals International news, CEO Sanj K. Patel sold 48,565 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $54.02, for a total value of $2,623,481.30. Following the completion of the sale, the chief executive officer owned 48,565 shares of the company’s stock, valued at approximately $2,623,481.30. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Michael R. Megna sold 6,625 shares of the firm’s stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $46.69, for a total value of $309,321.25. Following the completion of the sale, the chief accounting officer directly owned 27,418 shares of the company’s stock, valued at approximately $1,280,146.42. This represents a 19.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 653,301 shares of company stock valued at $34,046,073. 51.98% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

A number of institutional investors and hedge funds have recently modified their holdings of KNSA. EverSource Wealth Advisors LLC lifted its holdings in shares of Kiniksa Pharmaceuticals International by 140.4% during the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after purchasing an additional 532 shares during the period. Osaic Holdings Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals International during the second quarter worth about $31,000. KBC Group NV acquired a new stake in shares of Kiniksa Pharmaceuticals International during the first quarter worth about $34,000. Smartleaf Asset Management LLC acquired a new stake in shares of Kiniksa Pharmaceuticals International during the fourth quarter worth about $36,000. Finally, Nano Cap New Millennium Growth Fund L P acquired a new stake in shares of Kiniksa Pharmaceuticals International during the fourth quarter worth about $41,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Price Performance

KNSA opened at $52.30 on Wednesday. The business’s 50-day moving average is $50.64 and its two-hundred day moving average is $46.10. Kiniksa Pharmaceuticals International has a 1 year low of $26.27 and a 1 year high of $59.87. The firm has a market capitalization of $4.02 billion, a PE ratio of 58.11 and a beta of 0.12.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.09. The company had revenue of $214.27 million for the quarter, compared to analyst estimates of $206.11 million. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The firm’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.11 earnings per share. As a group, sell-side analysts expect that Kiniksa Pharmaceuticals International will post 1.24 EPS for the current year.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.